ASLAN Pharmaceuticals Limited (ASLN)

NASDAQ: ASLN · IEX Real-Time Price · USD
0.512
+0.020 (4.15%)
At close: Jun 29, 2022 3:54 PM
0.539
+0.026 (5.133%)
After-hours: Jun 29, 2022 5:13 PM EDT
4.15%
Market Cap 35.74M
Revenue (ttm) n/a
Net Income (ttm) -36.08M
Shares Out 69.74M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 94,818
Open 0.500
Previous Close 0.492
Day's Range 0.498 - 0.520
52-Week Range 0.356 - 3.810
Beta 2.36
Analysts Buy
Price Target 6.46 (+1,160.7%)
Earnings Date Aug 5, 2022

About ASLN

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop im... [Read more...]

Industry Biotechnology
IPO Date May 4, 2018
CEO Carl Firth
Employees 27
Stock Exchange NASDAQ
Ticker Symbol ASLN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ASLN stock is "Buy." The 12-month stock price forecast is 6.46, which is an increase of 1,160.73% from the latest price.

Price Target
$6.46
(1,160.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling...

MENLO PARK, Calif. and SINGAPORE, June 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments ...

ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference

MENLO PARK, Calif. and SINGAPORE, May 31, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to...

ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society f...

MENLO PARK, Calif. and SINGAPORE, May 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments t...

ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

MENLO PARK, Calif. and SINGAPORE, April 27, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022

MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments ...

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

MENLO PARK, Calif. and SINGAPORE, April 01, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on March 28, 2022, it received a written notice...

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022...

MENLO PARK, Calif. and SINGAPORE, March 28, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

MENLO PARK, Calif. and SINGAPORE, March 25, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic ...

- Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the “Late-breaking Research: Clinical Trials” session at the 2022 American Academy of Dermatology Annu...

ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis

ASLAN (ASLN) screens the first patient in the phase II dose ranging study evaluating its investigational monoclonal antibody in patients with atopic dermatitis.

ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with moderate-to-severe atopic dermatitis (AD).  Eblasakima...

ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis

MENLO PARK, Calif. and SINGAPORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments ...

ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004

-  Management to host the second webinar in ASLAN's A 4 series on Thursday, January 20, 2022, at 12:00pm ET

ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022

MENLO PARK, Calif. and SINGAPORE., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments ...

ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

MENLO PARK, Calif. and SINGAPORE, Oct. 26, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments ...

ASLAN Pharmaceuticals Announces Scientific Collaboration With Dr Emma Guttman-Yassky on Identification of ASLAN004-Sp...

MENLO PARK, Calif. and SINGAPORE, Oct. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments ...

ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004

- Management to host the first in a series of KOL webinars beginning Monday, October 25, 2021, at 10:00am ET

ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in ...

MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments ...

Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has announced topline data from its Phase 1 study of ASLAN004 for moderate-to-severe atopic dermatitis (AD).  In March 2021, ASLAN announced interim data from th...

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Derma...

- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile

ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference

MENLO PARK, Calif., and SINGAPORE, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments...

ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence E...

MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...

Implied Volatility Surging for ASLAN Pharmaceuticals (ASLN) Stock Options

Investors need to pay close attention to ASLAN Pharmaceuticals (ASLN) stock based on the movements in the options market lately.

ASLAN Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

SINGAPORE, Aug. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives ...

ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development

ASLAN Pharmaceuticals (NASDAQ: ASLN) has closed a secured loan facility provided by K2 HealthVentures (K2HV).  Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt ...